Losartan
Other / unclassified targets AGTR1, TGFB1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | COZAAR | — | 1995-12-29 – 2004-03-11 | fda.gov ↗ |
| Approved | US (FDA) | COZAAR | — | 1995-04-14 | fda.gov ↗ |
Trials 250 · started per year
Also used as a comparator or background therapy in 138 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT06796660 Background | Sep 2025 → Dec 2027 expected | chronic kidney disease | Liu Zhanghong | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT02704494 Background | Mar 2016 → Feb 2017 | diabetic kidney disease | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 0 | NCT01210430 Comparator | Jul 2010 → Jun 2015 | postural orthostatic tachycardia syndrome | New York Medical College | Completed | No outcome recorded |
| Phase 0 | NCT00720577 Comparator | Dec 2005 → Jul 2007 | peripheral arterial disease | Medtronic Endovascular | Completed | No outcome recorded |
| Phase 110 trials | ||||||
| Phase 1 | NCT05090449 Comparator | May 2019 → Apr 2020 | — | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 1 | NCT04049734 Comparator | Jan 2015 → Jan 2017 | acute pancreatitis | Ain Shams University | Completed | No outcome recorded |
| Phase 1 | NCT02166398 Comparator | Jun → Oct 2014 | — | Korea United Pharm. Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01570569 Comparator | Jan → Mar 2011 | — | Inje University | Completed | No outcome recorded |
| Phase 1 | NCT01187862 Background | Jul 2010 → Feb 2011 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT00856960 Comparator | Jan → Mar 2010 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00943852 Comparator | Aug → Dec 2006 | hypertensive disorder | Organon and Co | Completed | No outcome recorded |
| Phase 1 | NCT01149473 Comparator | Mar → Apr 2004 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT01124162 Comparator | Oct → Nov 2003 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT00001741 Background | Nov 1997 → Apr 2003 | cardiovascular disorder | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02263729 Comparator | Aug 2016 → Dec 2022 | — | James J. Irrgang | Terminated | No outcome recorded |
| Phase 216 trials | ||||||
| Phase 2 | NCT05212597 Comparator | Jan 2022 → Dec 2023 | aortic valve insufficiency | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT03897868 Comparator | Mar 2019 → Feb 2020 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 2 | NCT03632213 Comparator | Nov 2018 → May 2023 | mucopolysaccharidosis type 4A, mucopolysaccharidosis type 6 | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
| Phase 2 | NCT03467217 Comparator | Oct 2018 → Jun 2020 | NAFLD1 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Terminated | No outcome recorded |
| Phase 2 | NCT03295734 Comparator | May 2018 → Sep 2024 | hypertensive disorder | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT03217825 Comparator | Dec 2015 → Feb 2018 | essential hypertension | Windtree Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT02049307 Comparator | Oct 2014 → Dec 2018 | — | Hennepin Healthcare Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02010905 Comparator | Dec 2013 → Jan 2018 | postoperative ventricular dysfunction, tetralogy of fallot | Academic Medical Center - University of Amsterdam | Unknown | No outcome recorded |
| Phase 2 | NCT01989793 Comparator | Jul 2013 → Oct 2016 | muscular atrophy | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT01637623 Comparator | Jun 2012 → Jun 2015 | hypertensive disorder, obstructive sleep apnea syndrome | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 2 | NCT01447654 Comparator | Nov 2011 → Jun 2014 | hypertrophic cardiomyopathy | Henning Bundgaard | Completed | No outcome recorded |
| Phase 2 | NCT01371747 Background | Jun 2011 → May 2013 | chronic kidney disease, hypertensive disorder | Relypsa, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01199978 Background | Mar 2011 → Nov 2026 expected | acoustic neuroma | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01667614 Comparator | May 2010 → Mar 2012 | diabetic kidney disease, essential hypertension, type 2 diabetes mellitus | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00814255 Comparator | Dec 2008 → Jun 2013 | focal segmental glomerulosclerosis | NYU Langone Health | Completed | No outcome recorded |
| Phase 2 | NCT00649311 Comparator | Apr → Sep 2003 | hypertensive disorder | Pfizer | Terminated | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT07586371 Comparator | Apr → Jul 2026 overdue | diabetes mellitus, proteinuria | Dr Mudassar Saeed Pansota | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04078711 Background | Sep 2019 → Jun 2021 | essential hypertension | Jiangsu Province Hospital of Traditional Chinese Medicine | Unknown | No outcome recorded |
| Phase 2/3 | NCT00152633 Comparator | Sep 2005 → Jan 2006 | hypertensive disorder | University of Erlangen-Nürnberg Medical School | Withdrawn | No outcome recorded |
| Phase 333 trials | ||||||
| Phase 3 | NCT05619653 Comparator | Dec 2022 → Aug 2025 overdue | inflammation of heart layer, long COVID-19 | Valentina Puentmann | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04074551 Comparator | Jul 2019 → Mar 2020 | hyperlipidemia, hypertensive disorder | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT03082014 Comparator | Feb 2018 → Jul 2022 | cerebrovascular disorder | Ludwig-Maximilians - University of Munich | Terminated | No outcome recorded |
| Phase 3 | NCT02521233 Comparator | Nov 2016 → May 2017 | essential hypertension | EMS | Withdrawn | No outcome recorded |
| Phase 3 | NCT02521246 Comparator | Nov 2016 → May 2017 | essential hypertension | EMS | Withdrawn | No outcome recorded |
| Phase 3 | NCT02900729 Background | Oct 2016 → Aug 2017 | hypertensive disorder | Shanghai WiseGain Medical Devices Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT02620306 Comparator | Feb 2016 → Dec 2019 | chronic kidney disease | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02916602 Background | Apr 2015 → Sep 2016 | hypertensive disorder | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT02235909 Comparator | Mar 2015 → Nov 2019 | hypertensive disorder | Arbor Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02248961 Comparator | May 2014 → Aug 2015 | hypertensive disorder | R-Pharm | Completed | No outcome recorded |
| Phase 3 | NCT01805453 Comparator | Mar 2013 → Jan 2015 | glioblastoma | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT01541943 Comparator | Mar 2012 → Nov 2014 | essential hypertension, hyperlipidemia | HanAll BioPharma Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01051219 Comparator | May 2011 → Nov 2014 | metabolic dysfunction-associated steatohepatitis | Newcastle-upon-Tyne Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 3 | NCT01299376 Background | Jan → Nov 2011 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01302691 Background | Jan 2011 → Apr 2012 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00922480 Comparator | Dec 2008 → Jul 2009 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT00763893 Comparator | Sep 2008 → Jan 2014 | Marfan syndrome | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 3 | NCT00555217 Background | Jul 2008 → Sep 2014 | kidney disorder, type 2 diabetes mellitus | US Department of Veterans Affairs | Terminated | No outcome recorded |
| Phase 3 | NCT00670787 Comparator | Jun 2008 → Nov 2010 | hypertensive disorder | Kyushu University | Completed | No outcome recorded |
| Phase 3 | NCT01281787 Comparator | Apr 2008 → Jun 2013 | atrial fibrillation, lung cancer | European Institute of Oncology | Completed | No outcome recorded |
| Phase 3 | NCT00940680 Comparator | Apr → Nov 2008 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT00739674 Background | Feb 2008 → Jul 2009 | essential hypertension | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00280215 Comparator | Dec 2007 → Dec 2011 | primary hyperoxaluria | Mayo Clinic | Withdrawn | No outcome recorded |
| Phase 3 | NCT00723801 Comparator | Oct 2007 → Dec 2012 | Marfan syndrome | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00447603 Comparator | May → Oct 2007 | hypertensive disorder | Organon and Co | Terminated | No outcome recorded |
| Phase 3 | NCT00446563 Comparator | Mar 2007 → Mar 2010 | hypertensive heart disease | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00429364 Comparator | Jan 2007 → Feb 2014 | Marfan syndrome | Carelon Research | Completed | No outcome recorded |
| Phase 3 | NCT00519870 Comparator | Jan → Jul 2005 | pulmonary hypertension | Baskent University | Completed | No outcome recorded |
| Phase 3 | NCT00856271 Comparator | Aug 2004 → Feb 2005 | essential hypertension | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT00751751 Comparator | Jun 2003 → Apr 2005 | essential hypertension | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Completed | No outcome recorded |
| Phase 3 | NCT00857285 Comparator | May 2002 → Aug 2003 | essential hypertension | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT02269176 Comparator | Jul 2000 → Jan 2001 | essential hypertension | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02183701 Comparator | Apr → Dec 1998 | hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 449 trials | ||||||
| Phase 4 | NCT07547878 Comparator | Apr 2026 → Mar 2029 expected | chronic kidney disease, type 2 diabetes mellitus | Baylor Research Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07513883 Background | Mar 2026 → Sep 2028 expected | heart failure | Ziekenhuis Oost-Limburg | Recruiting | No outcome recorded |
| Phase 4 | NCT05843162 Comparator | Jun → Dec 2023 | essential hypertension, metabolic syndrome X | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 4 | NCT04662723 Background | May 2023 → Jun 2026 overdue | IgA glomerulonephritis | Schena Foundation | Recruiting | No outcome recorded |
| Phase 4 | NCT06431477 Comparator | Apr 2023 → Oct 2025 | diabetic kidney disease, essential hypertension | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 4 | NCT06718062 Comparator | May 2021 → May 2024 | essential hypertension | Hansung University | Completed | No outcome recorded |
| Phase 4 | NCT04394117 Comparator | Jun 2020 → Nov 2021 | COVID-19 | The George Institute | Completed | No outcome recorded |
| Phase 4 | NCT04330300 Comparator | Apr 2020 → Jul 2021 | COVID-19, essential hypertension | National University of Ireland, Galway, Ireland | Suspended | No outcome recorded |
| Phase 4 | NCT03953950 Background | Oct 2019 → Sep 2020 | end stage renal failure | Chiang Mai University | Unknown | No outcome recorded |
| Phase 4 | NCT03502031 Comparator | Oct 2018 → Oct 2022 | diabetic kidney disease | James A. Tumlin, MD | Unknown | No outcome recorded |
| Phase 4 | NCT03626259 Comparator | Aug 2018 → Jan 2019 | hypertensive disorder | Centro Universitario de Ciencias de la Salud, Mexico | Unknown | No outcome recorded |
| Phase 4 | NCT04222686 Comparator | Dec 2017 → Feb 2018 | type 2 diabetes mellitus | Yaounde Central Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02696564 Comparator | May 2017 → Mar 2021 | pulmonary emphysema | JHSPH Center for Clinical Trials | Completed | No outcome recorded |
| Phase 4 | NCT03578042 Comparator | Apr 2017 → Sep 2019 | hypertensive disorder | Hotel Dieu de France Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04061824 Comparator | May 2016 → Dec 2018 | hyperlipidemia, hypertensive disorder | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT03006952 Comparator | Apr → Sep 2015 | diabetic kidney disease | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT02958631 Comparator | Nov 2014 → Dec 2016 | hypertensive disorder | Chuncheon Sacred Heart Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02294539 Comparator | Aug 2014 → May 2016 | hypertensive disorder | Chong-Jin Kim | Completed | No outcome recorded |
| Phase 4 | NCT01964079 Comparator | Apr 2013 → Apr 2017 | hypertensive disorder | Wonju Severance Christian Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01774656 Background | Jan 2013 → Dec 2017 | advanced heart failure | University of Louisville | Unknown | No outcome recorded |
| Phase 4 | NCT01675362 Comparator | Aug 2012 → Aug 2014 | nephrolithiasis | Mansoura University | Completed | No outcome recorded |
| Phase 4 | NCT01766505 Comparator | Jun 2012 → Mar 2014 | hypertensive disorder | Chong Kun Dang Pharmaceutical | Terminated | No outcome recorded |
| Phase 4 | NCT01603940 Comparator | May 2012 → Jan 2015 | hypertensive disorder, type 2 diabetes mellitus | Hospital Universitario Pedro Ernesto | Completed | No outcome recorded |
| Phase 4 | NCT01230216 Comparator | Dec 2010 → Mar 2015 | coronary atherosclerosis, hypertensive disorder | Takeshi Morimoto | Terminated | No outcome recorded |
| Phase 4 | NCT01828359 Background | Aug 2010 → Jan 2013 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 4 | NCT01305850 Comparator | Jul 2010 → Aug 2011 | — | Chulalongkorn University | Unknown | No outcome recorded |
| Phase 4 | NCT01377285 Background | Jun 2010 → Dec 2018 | chronic renal failure syndrome | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01176032 Comparator | Jun 2010 → Apr 2013 | hypertensive disorder, hypertensive heart disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01271374 Comparator | Apr 2010 → Jun 2011 | hypertensive disorder | InVasc Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 4 | NCT00949884 Comparator | Aug 2009 → Jan 2010 | hypertensive disorder | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 4 | NCT01150201 Comparator | Jul 2009 → Aug 2014 | kidney disorder | The University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT00931710 Comparator | Jul 2009 → Jan 2010 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT01041963 Comparator | Jun 2009 → Jun 2010 | — | Chulalongkorn University | Unknown | No outcome recorded |
| Phase 4 | NCT00805311 Background | Apr 2009 → May 2014 | atherosclerosis, carotid stenosis, stroke disorder | Russian Cardiology Research and Production Center | Terminated | No outcome recorded |
| Phase 4 | NCT00716950 Comparator | Jul 2008 → Feb 2009 | essential hypertension | University of Pavia | Unknown | No outcome recorded |
| Phase 4 | NCT00673790 Comparator | May 2008 → Jul 2010 | hypertensive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT00492128 Background | Sep 2007 → May 2009 | hypertensive disorder | Yokohama City University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00456963 Comparator | Sep 2007 → Mar 2010 | diabetes mellitus, hypertensive disorder | Istituto Auxologico Italiano | Terminated | No outcome recorded |
| Phase 4 | NCT00675987 Comparator | May 2007 → Dec 2008 | hyperglycemia, hypertensive disorder, obesity disorder | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00369538 Comparator | Aug 2006 → ? | end stage renal failure, hypertensive disorder, proteinuria | University Hospital, Strasbourg, France | Suspended | No outcome recorded |
| Phase 4 | NCT00234858 Comparator | Mar 2004 → Apr 2006 | hypertensive disorder, metabolic syndrome X | Abbott | Completed | No outcome recorded |
| Phase 4 | NCT02200653 Comparator | May 2000 → Feb 2001 | essential hypertension | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT00198562 Comparator | Apr 2000 → Mar 2012 | hypertensive disorder | Ministry of Health, Labour and Welfare, Japan | Unknown | No outcome recorded |
| Phase 4 | NCT00140907 Comparator | Mar 2000 → Jan 2005 | hypertensive disorder | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT02200640 Comparator | Mar → Dec 2000 | hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT02172586 Comparator | Jan 2000 → Jan 2002 | hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT03276598 Comparator | Nov 1999 → Apr 2004 | essential hypertension | Helsinki University Central Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00813722 Comparator | Mar 1999 → Jan 2009 | hypertensive disorder | University of Sao Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT02238457 Comparator | — | heart failure | Baker Heart and Diabetes Institute | Withdrawn | No outcome recorded |
| Phase not applicable22 trials | ||||||
| — | NCT07683585 Comparator | Apr → Jul 2026 overdue | coronary artery disorder, hypertensive disorder | National Medical Research Center for Therapy and Preventive Medicine | Recruiting | No outcome recorded |
| — | NCT07568574 Background | Mar 2026 → May 2028 expected | — | Enhanced Emirates Limited | Enrolling by invitation | No outcome recorded |
| — | NCT07449000 Comparator | Feb 2026 → Feb 2027 expected | corneal disorder | Autonomous University of Nuevo León | Recruiting | No outcome recorded |
| — | NCT06539806 Comparator | Jul 2024 → Aug 2026 overdue | malignant pancreatic neoplasm | Tanta University | Recruiting | No outcome recorded |
| — | NCT06344247 Background | Sep 2023 → Sep 2025 | chronic kidney disease, obesity disorder | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT05753696 Comparator | Apr 2023 → Oct 2024 | diabetic kidney disease, hypertensive disorder, impaired renal function disease, proteinuria | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT05479097 Background | Feb → Aug 2023 | hypertensive disorder | University of Wisconsin, Madison | Completed | No outcome recorded |
| — | NCT05064904 Comparator | Feb 2019 → Jan 2024 | acute kidney injury | National Taiwan University Hospital | Unknown | No outcome recorded |
| — | NCT04278495 Comparator | Sep 2014 → Dec 2018 | urinary tract obstruction | Mansoura University | Completed | No outcome recorded |
| — | NCT02121041 Comparator | May 2014 → Sep 2015 | hypertensive disorder | Anthony J Viera, MD, MPH | Completed | No outcome recorded |
| — | NCT01854814 Comparator | Jul 2013 → Feb 2022 | IgA glomerulonephritis | Fan Fan Hou | Completed | No outcome recorded |
| — | NCT01845688 Background | Nov 2011 → Feb 2016 | idiopathic membranous glomerulonephritis | wanglin | Completed | No outcome recorded |
| — | NCT00981929 Comparator | Sep → Dec 2009 | — | University of Southern Denmark | Terminated | No outcome recorded |
| — | NCT01982695 Comparator | Mar 2009 → Aug 2012 | Duchenne muscular dystrophy, cardiomyopathy | Nationwide Children's Hospital | Completed | No outcome recorded |
| — | NCT00647257 Comparator | Apr → Dec 2008 | atrial fibrillation | Chung Shan Medical University | Unknown | No outcome recorded |
| — | NCT01015937 Comparator | Mar 2008 → Jun 2009 | diabetic kidney disease, proteinuria | Shaheed Faghihi Hospital | Completed | No outcome recorded |
| — | NCT00630708 Comparator | Feb 2008 → Mar 2014 | chronic kidney disease | Nanfang Hospital, Southern Medical University | Terminated | No outcome recorded |
| — | NCT04954560 Comparator | Jan 2008 → Jan 2010 | — | Medical University of Lodz | Completed | No outcome recorded |
| — | NCT00378443 Background | Jan 2006 → Jun 2007 | IgA glomerulonephritis | Peking University | Unknown | No outcome recorded |
| — | NCT00364988 Background | Jan → Dec 2005 | diabetic kidney disease, type 2 diabetes mellitus | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| — | NCT00565396 Comparator | Sep 2004 → Jul 2008 | chronic kidney disease, proteinuria | Shanghai Municipal Health Bureau | Unknown | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2010-04-07 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Final Approval of Generic Hyzaar® and Cozaar® tevapharm.com ↗ |
| 2010-03-02 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Favorable Court Ruling in Generic Hyzaar® and Cozaar® Litigation tevapharm.com ↗ |
| 2006-06-14 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval of Losartan Potassium & Hydrochlorothiazide Tablets tevapharm.com ↗ |
| 2006-05-28 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval for Generic Cozaar® Tablets tevapharm.com ↗ |
Evidence & citations 44 cited values
Every value below carries the sentence it was read from. 393 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Losartán | “The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ...” NCT01774656 ↗371“The study intervention will be a heart failure with reduced ejection fraction (HFrEF) polypill consisting of bisoprolol (beta-blocker), losartan (ARB), eplerenone (MRA), and...” NCT07569640 ↗ “HFrEF polypill strength 1: bisoprolol 2.5 mg + losartan 25 mg + eplerenone 25 mg + dapagliflozin 10 mg; HFrEF polypill strength 2: bisoprolol 5 mg + losartan 50 mg + eplerenone...” NCT06831864 ↗ “Two equally loaded capsules containing: Melatonin (2.0 mg) Nicotine (1.0 mg) Bupropion (37.5 mg) Repaglinide (0.25 mg) Losartan (12.5 mg) Omeprazole (10 mg) Chlorzoxazone...” NCT03563287 ↗ “Oral losartan given in the dose of 50 mg one hour before ERCP was studied in the prevention of post ERCP pancreatitis in 50 patients indicated for ERCP in comparison with...” NCT04049734 ↗ “One of ARBs(Valsartan, Olmesartan, Candesartan, Telmisartan, Fimasartan, Losartan and Irbesartan) and one of statins(Rosuvastatin, Atorvastatin, Pitavastatin, Simvastatin,...” NCT04061824 ↗ “Midazolam, repaglinide, and losartan (CYP probe substrates) and, for female participants, estradiol/norethisterone acetate (hormonal probe substrate), administered orally (PO)...” NCT07704658 ↗ “Pharmacokinetics of a Fixed-Dose Combination Product of Amlodipine, Losartan, Ezetimibe, and Rosuvastatin and Its Comparison with Co-administration of Four Individual...” PMID 38775910 ↗ May 2024 “Losartán dosage: 12.5 mg /day for patients \< 50 Kg or 25 mg/day for patients \> 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for...” NCT01145612 ↗ “The objective of this study was to evaluate the efficacy and tolerability of a triple combination of amlodipine/losartan/rosuvastatin in patients with hypertension and...” PMID 29150250 ↗ Nov 2017 “Two randomized studies were designed to assess the safety, tolerability and efficacy of losartan 100 mg (L100) plus hydrochlorothiazide 12.5 mg (H12.5) in a single fixed-dose...” PMID 24990091 ↗ Jul 2014 “probe drugs for simultaneous phenotyping of CYP1A2 (caffeine), CYP2B6 (efavirenz), CYP2C9 (losartan), 2C19 (omeprazole), CYP2D6 (metoprolol), and CYP3A4 (midazolam)” PMID 26123704 ↗ Jan 2016 “Blood Pressure Control: Antihypertensive drugs such as amlodipine tablets (5 mg qd), nifedipine tablets (30 mg qd), or losartan tablets (100 mg qd) can be selected.” NCT06796660 ↗ “Angiotensin II receptor antagonists ,these medicines have names that end in "sartan".For examples:losartan,candesartan,irbesartan,olmesartan,telmisartan,valsartan” NCT01377285 ↗ “ZYN002 (transdermal), midazolam (oral), omeprazole (oral), losartan (oral), dextromethorphan (oral), caffeine (oral), repaglinide (oral), bupropion (oral)” NCT06930872 ↗ “Japanese patients with uncontrolled essential hypertension received single-blind losartan 50 mg/hydrochlorothiazide 12.5 mg (L50/H12.5) for 8 weeks.” PMID 25271811 ↗ Oct 2014 “A Randomized, Double-Blind, Two Arm, Parallel Group Health Assessment Study of Losartan or Atenolol in Patients With Mild to Moderate Hypertension” NCT00541684 ↗ “RAAS (Lisinopril, Enalapril, Perindopril, Losartan, and Valsartan taken each day at maximum tolerated dose that will different for each subject)” NCT03502031 ↗ “Oral drug cocktail consisting of caffeine (100 mg), dextromethorphan (30 mg), losartan (25 mg), midazolam syrup (2 mg), and omeprazole (20 mg).” NCT06693960 ↗ “If the patient is intolerant to either of these, an angiotensin receptor blocker (ARB)(Candesartan, Losartan, Valsartan) will be introduced.” NCT05637853 ↗ “They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week” NCT01675362 ↗ “Single oral administration of caffeine (100mg), omeprazole (20mg), losartan (25mg), dextromethorphan (30mg), and midazolam (1mg)” NCT04201197 ↗ “modified "karolinska cocktail" (dextromethorphan, caffeine, losartan, omeprazole and paracetamol) before bariatric surgery” NCT01086722 ↗ “INV-144 is a combination drug product consisting of losartan potassium (50mg) and alpha lipoic acid (600 mg)” NCT01398423 ↗ “A combination of finerenone 10 mg, empagliflozin 12.5 mg, and losartan 50 mg or 100 mg within a polycapsule.” NCT06143566 ↗ “The study recommends physicians to select evidence-based ARBs such as candesartan or valsartan or losartan.” NCT04591210 ↗ “Cozzar tablet: Losartan potassium 50mg, 100mg/cap, orally, 1 capsule once a day during 16 weeks” NCT01766505 ↗ “Candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan” NCT04330300 ↗ “Losartan is an ANG II receptor antagonist which attenuates ET-1 production.” NCT03371823 ↗ “prescription of antihypertensives (amlodipine and/or losartan OR enalapril)” NCT05479097 ↗ “ARB (second line alternative to ACEi): valsartan, losartan or candesartan” NCT07513883 ↗ “includes midazolam, caffeine, losartan, omeprazole, and dextromethorphan” NCT03505853 ↗ “40-80 mg benazepril plus 25-100 mg losartan orally once or twice daily” NCT00907374 ↗ “Group A patients will be prescribed ARBs (losartan 50 mg/day)” NCT07586371 ↗ “eprosartan, irbesartan, losartan, olmesartan, telmisartan” NCT00684489 ↗ “MICARDIS® (Telmisartan) and COZAAR® / LORZAAR® (Losartan)” NCT02200653 ↗ “spironolactone 25 mg once daily added to losartan” NCT01667614 ↗ “equal to Losartan 50mg or Captopril 25mg bid” NCT05064904 ↗ “amlodipine, Losartan, Chlorthalidone FDC” NCT02916602 ↗ “losartan 50 mg daily in adult patients” NCT00280215 ↗ “use losartan to control blood pressure” NCT01230216 ↗ “PO Losartan 25mg every 24 hours.” NCT04428268 ↗ “Amlodipine 5mg /Losartan 100mg” NCT01828359 ↗ “Losartan 50 mg : 1cp de 50mg” NCT01443039 ↗ “the drug Cozaar (losartan)” NCT00275639 ↗ “Losartan 100mg(Cozaar)” NCT04081844 ↗ “Losartan 50 mg daily” NCT03357653 ↗ “COZAAR® (Losartan)” NCT02200640 ↗ “Losartan 150mg/d” NCT02817360 ↗ “Losartan 50mg” NCT02056743 ↗ “Losartan” NCT04222686 ↗ “losartan” NCT04662723 ↗ “losartan” NCT01015937 ↗ “Losartan” NCT05232370 ↗ “Losartan” NCT02735707 ↗ |
| Known as | Allisartan | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | Angizaar | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | Aradois | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | Cozaar | “The purpose of this research study is to determine if after one year of treatment telmisartan (MICARDIS, GLIOSARTAN, KINZAL, KINZALMONO, PREDXAL, PRITOR, SAMERTAN, TELMISARTAN)...” NCT00168857 ↗20“This study was conducted to evaluate and compare the effectiveness of Amodipin® (amlodipine camsylate) with that of Cozaar® (losartan potassium) in hypertensive patients with...” NCT01830517 ↗ “in addition to local PRP injection, 50 mg / day of LOSARTAN (Cozaar® 50 mg film-coated tablets) were administrated to the study group orally every morning from day 5 and till...” NCT05827484 ↗ “They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week” NCT01675362 ↗ “The commonly prescribed antihypertensive drug losartan (brand name: Cozaar; UK licensed for 20 years)” NCT03763409 ↗ “COZAAR (losartan potassium) is an angiotensin II receptor (type AT1) antagonist.” NCT03217825 ↗ “single-dose losartan potassium (Cozaar; weight-adjusted 25mg or 50mg)” NCT06636812 ↗ “MICARDIS® (Telmisartan) and COZAAR® / LORZAAR® (Losartan)” NCT02200653 ↗ “losartan 100 mg tablets (test) versus Cozaar® (reference)” NCT01124162 ↗ “7-day losartan (Cozaar, 50mg; oral tablet) with 7-day BA” NCT07017023 ↗ “oral single-dose losartan potassium (Cozaar; 50mg)” NCT06628154 ↗ “the drug Cozaar (losartan)” NCT00275639 ↗ “Cozaar® (losartan) 50 mg” NCT00496834 ↗ “50mg losartan (Cozaar)” NCT05828940 ↗ “Losartan 100mg(Cozaar)” NCT04081844 ↗ “COZAAR® (Losartan)” NCT02200640 ↗ |
| Known as | Cozaar Tab. | “Cozaar Tab.(Losartan) 50mg(100mg) + Anydipine-S(S-amlodipine) Tab. 2.5mg” NCT05843162 ↗ |
| Known as | Cozaar: losartan | “Cozaar: losartan” NCT00981747 ↗ |
| Known as | COZZAR | “Losartan (COZZAR®)” NCT05090449 ↗ |
| Known as | Cozzar tablet | “Cozzar tablet: Losartan potassium 50mg, 100mg/cap, orally, 1 capsule once a day during 16 weeks” NCT01766505 ↗ |
| Known as | DU PONT-753 | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | DUP 753 | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | Dup-89 | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | E-3340 | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | HGP1405 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02387554 ↗ |
| Known as | L-158086 | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | L50 | “50 mg losartan potassium (L50), 12.5 mg hydrochlorothiazide (H12.5), and 5 mg amlodipine besylate (A5)” NCT01302691 ↗ |
| Known as | LORZAAR | “MICARDIS® (Telmisartan) and COZAAR® / LORZAAR® (Losartan)” NCT02200653 ↗ |
| Known as | LOS | “olmesartan medoxomil (OM) versus losartan potassium (LOS)” PMID 22763801 ↗ Jul 2012 |
| Known as | Losacar | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | Losaprex | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | losartan (Cozaar) | “losartan (Cozaar)” NCT02238457 ↗ |
| Known as | losartan (Cozaar, Merck Sharp & Dohme, Wilmington, DE, USA) | “losartan (Cozaar, Merck Sharp & Dohme, Wilmington, DE, USA)” NCT00519870 ↗ |
| Known as | Losartan (generic name) | “Losartan (generic name)” NCT01124175 ↗ |
| Known as | Losartan also known as Cozaar | “Losartan also known as Cozaar” NCT01051219 ↗ |
| Known as | Losartan monopotassium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | Losartan potassium | “This study was conducted to evaluate and compare the effectiveness of Amodipin® (amlodipine camsylate) with that of Cozaar® (losartan potassium) in hypertensive patients with...” NCT01830517 ↗31“This study will compare the advantages and disadvantages of azilsartan and classical ARB drug losartan potassium in terms of proteinuria, blood pressure control and renal...” NCT05753696 ↗ “Losartan potassium (losartan) is an angiotensin II receptor blocker (ARB) that reduces PAI-1 production and improves insulin sensitivity that has been proposed as a treatment...” PMID 29992039 ↗ Jun 2018 “IgAN patients will be randomized assigned to the Abelmoschus manihot group (in the form of a huangkui capsule, 2.5 g, three times per day) and the losartan potassium group...” PMID 28395659 ↗ Apr 2017 “Cozzar tablet: Losartan potassium 50mg, 100mg/cap, orally, 1 capsule once a day during 16 weeks” NCT01766505 ↗ “Losartan potassium is an angiotensin II receptor blocker acting on the AT 1 receptor subtype” NCT03467217 ↗ “COZAAR (losartan potassium) is an angiotensin II receptor (type AT1) antagonist.” NCT03217825 ↗ “Losartan potassium 100 mg tablet, a product of Schering-Plough, S.A. C.V.” NCT05090449 ↗ “single-dose losartan potassium (Cozaar; weight-adjusted 25mg or 50mg)” NCT06636812 ↗ “MK0954, losartan potassium / Duration of Treatment - 12 weeks” NCT00449111 ↗ “MK0954, losartan potassium/Duration of Treatment: 18 weeks” NCT00140959 ↗ “MK0954, losartan potassium/Duration of Treatment: 20 weeks” NCT00140985 ↗ “losartan potassium 100mg treatment (A/L 5/100) group” PMID 29150250 ↗ Nov 2017 “oral single-dose losartan potassium (Cozaar; 50mg)” NCT06628154 ↗ “Cozaar (Losartan Potassium 25mg)” NCT04278495 ↗ “Drug: Losartan Potassium” NCT04632589 ↗ “Drug: losartan potassium” NCT00140907 ↗ “Drug: Losartan Potassium” NCT03763409 ↗ “Drug: losartan potassium” NCT00447603 ↗ “Drug: losartan potassium” NCT00943852 ↗ “Losartan potassium 50mg” NCT03147092 ↗ |
| Known as | Losartan potassium component of hyzaar | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | Losartic | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | Losata | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | Lozap | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | LST | “The antihypertensive efficacy and tolerability of losartan (LST) in fixed combination with hydrochlorothiazide (HCTZ) has not been compared to those of amlodipine monotherapy in Asians.” PMID 19949604 ↗ Apr 2009 |
| Known as | MK0954 | “MK0954, losartan potassium / Duration of Treatment - 12 weeks” NCT00449111 ↗4“MK0954, losartan potassium/Duration of Treatment: 20 weeks” NCT00140985 ↗ “MK0954, losartan potassium/Duration of Treatment: 18 weeks” NCT00140959 ↗ “MK0954, losartan / Duration of Treatment: mean 3.4 years” NCT00308347 ↗ “Losartan (MK0954) / Losartan + HCTZ (MK0954A)” NCT00546052 ↗ |
| Known as | MK0954, /Duration of Treatment : 5 Years | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00338260 ↗ |
| Known as | NSC-758699 | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | Nu-lotan | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | Presartan-50 | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | Reslio | “Losartan Based Therapy Reslio® (Losartan) and Resilo-h® (Losartan+Hydrochlorthiazide)” NCT03978884 ↗ |
| Known as | Tancin | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Known as | Zaart | ChEMBL registry synonym — accepted as the source's own label CHEMBL191 ↗ |
| Action | Inhibit | “Specific Aim 1 To recruit 285 type 1 diabetic patients who do not have hypertension, diabetic nephropathy, or predictive levels of microalbuminuria into a 5-year study to...” NCT00143949 ↗1“Type-1 angiotensin II receptor antagonist” CHEMBL191 ↗ |
| Modality | Other / unclassified | “angiotensin receptor blocker” NCT02190318 ↗ |
| Route | Oral | “50-mg losartan oral tablet” NCT00090259 ↗ |
| Target | AGTR1 | “Type-1 angiotensin II receptor antagonist” CHEMBL191 ↗ |
| Target | TGFB1 | “Losartan is a known anti-fibrotic agent via blocking of TGF-B1.” NCT04212650 ↗ |